By Mike Montemarano, Associate Editor10.16.20
The Council for Responsible Nutrition (CRN), a trade organization representing the dietary supplements industry, recently took issues with the way an analysis published in Neurology Clinical Practice portrayed the state of the cognitive support supplements category.
The analysis, authored by Pieter A. Cohen, MD, from Harvard Medical School, et al, “Five unapproved drugs found in cognitive enhancement supplements,” stated that its objective was to identify the presence of unapproved pharmaceutical drugs in over-the-counter dietary supplements marketed to improve memory and cognitive function. The authors of the study used two supplement databases to identify products containing either omberacetam, aniracetam, phenylracetam, or oxiracetam, four drugs classified as piracetam analogues which are not approved for human use in the U.S.
Piracetam analogs are used in select countries as medications used to treat a number of neurological disorders or injuries.
The supplement databases used in the study were the National
The analysis, authored by Pieter A. Cohen, MD, from Harvard Medical School, et al, “Five unapproved drugs found in cognitive enhancement supplements,” stated that its objective was to identify the presence of unapproved pharmaceutical drugs in over-the-counter dietary supplements marketed to improve memory and cognitive function. The authors of the study used two supplement databases to identify products containing either omberacetam, aniracetam, phenylracetam, or oxiracetam, four drugs classified as piracetam analogues which are not approved for human use in the U.S.
Piracetam analogs are used in select countries as medications used to treat a number of neurological disorders or injuries.
The supplement databases used in the study were the National
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
